Yongchang C. Zhang

No.87 Xiangya Road
Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 162 publications

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: June 24, 2026

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 21, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

FGF2-Based Cyclic Peptide PET Tracer for Noninvasive Detection of FGFR1 Expression in Non-Small Cell Lung Cancer.

FGF2-Based Cyclic Peptide PET Tracer for Noninvasive Detection of FGFR1 Expression in Non-Small Cell Lung Cancer.

Journal: Journal of medicinal chemistry

Published: February 17, 2026

Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial.

Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 09, 2026

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Journal: Cell reports. Medicine

Published: January 07, 2026

Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.

Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.

Journal: Chinese medical journal pulmonary and critical care medicine

Published: January 06, 2026

Editorial: Treatment response and resistance to targeted therapies for NSCLC.

Editorial: Treatment response and resistance to targeted therapies for NSCLC.

Journal: Frontiers in oncology

Published: January 03, 2026

Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.

Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.

Journal: JCO oncology practice

Published: December 15, 2025

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Journal: The Lancet regional health. Western Pacific

Published: October 30, 2025

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.

Journal: The New England journal of medicine

Published: October 22, 2025

Showing 1-12 of 162

Last Updated: 09/26/2026